
Studds Accessories Ltd, the largest producer of two-wheeler helmets in India, launched its Initial Public Offer (IPO) on October 30, 2025. The bidding window for Studds Accessories IPO will be closing today on November 3, 2025. The basis of allotment will be finalised by November 4, 2025, and the tentative listing on BSE and NSE is scheduled for November 7, 2025.
[November 03, 2025, 11:36 AM]
On Day 3, the Studds Accessories IPO saw a subscription rate of 11.80 times, according to NSE data as of November 03, 2025, 11:36 am. The public issue was subscribed 11.16 times in the Retail Individual Investors (RIIs) category, 26.39 times in the Non-Institutional Investors (NII) category and 1.97 times in the Qualified Institutional Buyers (QIBs) category.
Explore other Upcoming IPOs on BSE and NSE.
Studds Accessories IPO is a book-building issue of ₹455.49 crore, comprising an offer for sale (OFS) of 0.78 crore shares by promoters and other selling shareholders. The price band is set between ₹557 and ₹585 per share. The minimum lot size is 24 shares per lot, and the minimum investment amount for retail investors is ₹14,625 (25 shares) (based on the upper price).
IIFL Capital Services Limited and ICICI Securities Limited are the book-running lead managers for the IPO. MUFG Intime India Private Limited is the registrar for the issue.
Check out newly Listed IPOs on BSE and NSE.
As the IPO is an offer for sale, the company will not receive any proceeds; they will be allocated directly to the selling shareholders.
Studds Accessories designs, manufactures, and sells two-wheeler helmets, two-wheeler luggage, gloves, helmet locking devices, rain suits, riding jackets and eyewear under the brand names ‘Studds’ and ‘SMK’. In FY 2025, the company has sold around 7.40 million helmets.
The company is the largest two-wheeler helmet player in India (by revenue in FY 2024) and the world’s largest two-wheeler helmet player (by volume in calendar year 2024).
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here